ArticleOncology letters2026
Individualized management strategies for advanced non-small cell lung cancer with
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR) mutations are major oncogenic drivers in non-small cell lung cancer (NSCLC). These alterations, particularly prevalent in lung adenocarcinoma among the Chinese population, include the exon 19 deletion (19del), L858R point mutation and the less frequent L861Q variant. However, to the best of our knowledge, no standardized treatment regimen exists for patients harboring both common and rare EGFR mutations. The current study presents a case of advanced metastatic lung adenocarcinoma with concurrent EGFR 19del and L861Q mutations, managed with tyrosine kinase inhibitors targeting EGFR and dynamic plasma circulating tumor DNA (ctDNA) monitoring. The patient achieved a progression-free survival time of 11 months. Serial plasma ctDNA monitoring detected molecular progression, characterized by an increase in total ctDNA and a rising
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.